Pharmacogenomics and pharmacogenetics will have a major impact on the future of health care.
Pharmacogenetics is the study of the genetic basis for individuals・variable drug responses,
and is being applied with increasing frequency at the clinical level. These efforts rely on
pharmacogenomics, the genome-wide analysis of the genetic determinants of drug efficacy and
toxicity. The cornerstone is the ability to identify genetic variations (polymorphisms) that alter
an individuals response to a drug.
This BCC report presents a comprehensive analysis of the current market for pharmacogenomics and
its future direction. Currently, the field remains immature. This leaves enormous room for growth.
This growth potential over a five-year period to 2009 is assessed. Of particular interest are the
markets for SNP identification, genotyping and diagnostics.
Also of interest is the market for specific drugs developed through the use of pharmacogenomics.
Only a handful of such therapeutics have entered clinical use as of 2005. In each case, there is an
examination of the drug development process, major challenges and achievements and where applicable,
the projected market for each of these drugs through 2009.
View Cart
